標題: Follow-on RifAximin for the Prevention of recurrence following standard treatment of Infection with Clostridium Difficile (RAPID): a randomised placebo controlled trial
作者: Major, Giles
Bradshaw, Lucy
Boota, Nafisa
Sprange, Kirsty
Diggle, Mathew
Montgomery, Alan
Jawhari, Aida
Spiller, Robin C.
Bradshaw, Lucy
Boota, Nafisa
Fahy, Sarah
Allen, Rob
Walker, Sarah
Sprange, Kirsty
Childs, Margo
Bumphrey, Gill
Simpkins, Daniel
Whitaker, Keith
Hodgson, Sheila
Cook, Bernie
Falcone, Yirga
Diggle, Mathew
Budd, Patrick
Sloan, Tim
Jalanka, Jonna
Jawhari, Aida
Ahmad, Saqib
Foreman, Helen
Garratt, Jill
Pyke, Shirley
Rorison, Brian
Patel, Mina
Shonde, Anthony
Kemp, Sam
Allsop, Lynn
Mossad, Alison
Heeley, Cheryl
Taylor, Nicholas
Misra, Sharat
Foley, Stephen
Wade, Lynn
Clarke, Rebecca
Kewley, Rebecca
Palmer, Sally
Boam, Samantha
Haigh, Steve
Hussain, Yassar
Mossad, Alison
Downes, Charlotte
Grant, Claire
Barnes, Elizabeth
Williams, Jessica
Horne, Kerry
Kimber, Lindsey
Harper, Margaret
Fox, Peter
Humphries, Ryan
Brear, Tracy
Abbott, Wendy
Craig, Sarah
Yazdani, Farah
Forrest, Helen
Lacey, Julia
Garsed, Klara
Turner, Rebecca
Hebden, John
Humphreys, John
Fofie, Joyce
Sorrel, Julie
Armitage, Kelsey
Ryalls, Kim
Davy, Mark
Agyemang, Michael
Birchall, Sarah
Booth, Stephen
Partridge, David
Lithgow, Jim
Whileman, Amanda
Adams-Heath, Charlotte
Elphick, David
Hall, Emily
Naylor, Greg
Toms, Julie
Dear, Keith
Stevenson, Lesley
Wright, Stephanie
Baker, Alison
Yeomans, Angela
Owen, Charlotte
Adams, Colene
Wilfred, Doyin
Button, Heather
Butterworth, Jeffery
Jones, John
Carnahan, Mandy
Painter, Sharen
Dhar, Anjan
Clark, Anne
Shaw, Claire
Deane, Jill
Stevenson, Lynsey
Wood, Michelle
Henthorn, Rebecca
Nendick, Richard
Kennedy, Anthony
Gamble, Penny
Burnip, Rachel
Nayar, Deepa
Hobday, David
Edwards, Michelle
Oates, Pauline
Beard, Roderick
Settle, Chris
Dungla, Eleanor
Crosbie, James
Holden, Jill
Painter, John
Richardson, Leigh
Fairle, Louise
Carr, Pauline
Cowlam, Simon
Butler, Stephan
Dixon, Andrew
Das, Debashish
Bharkhada, Dhiren
Kessell, Jeannie
Tate, Jemma
Novasg, Jo
Fosbrook, Julie
Raymode, Parizade
Harris, Andrew
Homer, Anthony
Oglesby, Arabis
Jeppesen, Catherine
Maitland, Dennise
Gibbins, Jackie
Wilshire, Simon
Noyle, Emma
Moss, Gloria
Ashcroft, Pauline
Skotnicka, Agnieska
Boyce, Andrea
Wheater, Gill
Thompson, Jane
Wong, Jason
Tregonning, Julie
Ramadas, Arvind
Sweeney, Danielle
Dallal, Helen
McGivern, Julie
Jackson, Wendy
Hanson, Clare
Brewer, Chris
Graham, Clive
Hetherington, Emily
Crowther, Hannah
Fairlamb, Helen
Thronthwaite, Sarah
Wilson, Toni
Poultney, Una
Mcskeane, Anna
Crucerson, Elena
King, Barbara
Merritt, Carley
Palmer, Caroline
Narh, Christina
Williams, Claire
Ashrafi, Mariam
Brown, Matthew
Topping, Megan
Stanford, Sophia
Swanson, Linda
Lloyd, David
Cooke, Duncan
Hellstrom, Johanna
Gordon, John
Elliott, Julie
Gamble, Karen
Gwiggner, Markus
Brown, Matthew
Croome, Victoria
Frith, Angela
Booker, Cheryl
Ball, Darren
Levell, Emma
Smith, Michelle
Stroud, Mike
Kean, Miranda
Fenn, Monica
Dharmasiri, Suranda
Razanskaite, Violetia
Ford, Meirion
Said, Rasha
Day, Tracey
Jones, Graeme
Mitchell, Julie
Bitouche, Yazmin
Hammond, Clare
Sahota, Gurminder
Steed, Helen
Rankin, Jayne
Patel, Jaynesh
Kauldhar, Kelly
Green, Marie
Reid, Matthew
Cooper, Michael
Agrawal, Anurag
Hill, Gavin
Foot, Helen
Dumville, Jane
Fairweather, Mark
Lancaster, Nicola
Hone, Sarah
Commey, Thelma
Allcock, Clare
Smith, Jacqueline
Mohankumar, Lakshimpriya
Gidda, Ranjit
Ishaq, Sauid
Merotra, Susan
Stacey, Danielle
Das, Dave
Taylor, Emma
Foley, Gail
Curtis, Janette
Orrell, Lucy
Holland, Maureen
Taylor, Moira
Scanlon, Sarah
Graham, Susan
Mahmood, Zahid
Dugh, Parveen
Gyawali, Pranab
Tsui, Salina
McClusky, Theresa
Wiseman, WanTei
Rommel, Butwana
Patel, Meera
Premchand, Purushothaman
Spencer, Kevin
Davis, Rob
Goodye, Sacha
Rahman, Anisur
Witele, Eric
Notcheva, Gaynor
Chung-Faye, Guy
Flanagan, Joanna
Mandar, Kirandip
Choong, Lee Meng
Adedeji, Oluwafunmilayo
Tashi, Surabhi
交大名義發表
National Chiao Tung University
公開日期: 1-七月-2019
摘要: Background Clostridium difficile infection (CDI) recurs after initial treatment in approximately one in four patients. A single-centre pilot study suggested that this could be reduced using ' follow-on' rifaximin treatment. We aimed to assess the efficacy of rifaximin treatment in preventing recurrence. Methods A multisite, parallel group, randomised, placebo controlled trial recruiting patients aged >= 18 years immediately after resolution of CDI through treatment with metronidazole or vancomycin. Participants received either rifaximin 400 mg three times a day for 2 weeks, reduced to 200 mg three times a day for a further 2 weeks or identical placebo. The primary endpoint was recurrence of CDI within 12 weeks of trial entry. Results Between December 2012 and March 2016, 151 participants were randomised to either rifaximin or placebo. Primary outcome data were available on 130. Mean age was 71.9 years (SD 15.3). Recurrence within 12 weeks was 29.5% (18/61) among participants allocated to placebo compared with 15.9% (11/69) among those allocated to rifaximin, a difference between groups of 13.7% (95% CI -28.1% to 0.7%, p=0.06). The risk ratio was 0.54 (95% CI 0.28 to 1.05, p=0.07). During 6-month safety follow-up, nine participants died in each group (12%). Adverse event rates were similar between groups. Conclusion While ' follow-on' rifaximin after CDI appeared to halve recurrence rate, we failed to reach our recruitment target in this group of frail elderly patients, so the estimated effect of rifaximin lacks precision. A meta-analysis
URI: http://dx.doi.org/10.1136/gutjnl-2018-316794
http://hdl.handle.net/11536/152332
ISSN: 0017-5749
DOI: 10.1136/gutjnl-2018-316794
期刊: GUT
Volume: 68
Issue: 7
起始頁: 1224
結束頁: 1231
顯示於類別:期刊論文